🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

GGP Misses FFO And Revenue Estimates In Q1, NOI Declines

Published 05/02/2018, 09:00 PM
Updated 07/09/2023, 06:31 AM
BPYU
-

Have you been eager to see how GGP Inc. (NYSE:GGP) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based retail real estate investment trust (REIT) earnings release this morning:

A FFO Miss

GGP came out with funds from operations (FFO) per share of 35 cents, missing the Zacks Consensus Estimate of 37 cents.

Results reflect year over year decline in same-store NOI

How Was the Estimate Revision Trend?

The company, has a mixed surprise history, beating estimates in two occasions and meeting in the other two, with an average positive surprise of 4.1%. This is depicted in the graph below.

General Growth Properties, Inc. Price and EPS Surprise

Revenue Came Lower Than Expected

GGP posted revenues of $574.2 million, which missed the Zacks Consensus Estimate of $603 million. However, it compared favorably with the year-ago number of $566.3 million.

Key Developments to Note

GGP’s development and redevelopment activities totaled $1.5 billion. However, the company recorded 8% decline in same-store NOI year over year.

On Mar 26, 2018, GGP announced that it has reached an agreement with Brookfield Property Partners, per which Brookfield will acquire the GGP shares it doesn’t own yet for nearly $15.3 billion, gaining complete ownership of the second-largest U.S. mall owner.

What Zacks Rank Says

GGP has a Zacks Rank #2 (Buy). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this GGP earnings report!

Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >



General Growth Properties, Inc. (GGP): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.